Immatics N.V

NASDAQ:IMTX   1:33:09 PM EDT
9.90
-0.15 (-1.49%)
Products, Strategic Combinations

Immatics And Bristol Myers Squibb Enter Into Global Exclusive License For Immatics’ TCR Bispecific Program Ima401

Published: 12/14/2021 12:23 GMT
Immatics N.V (IMTX) - Immatics and Bristol Myers Squibb Enter Into Global Exclusive License for Immatics’ Tcr Bispecific Program Ima401.
Immatics NV - ‍​cos to Collaborate on Development With Co Retaining Co-promotion Option in U.S.immatics NV - ‍​bristol Myers Squibb Secures Global Exclusive License to Co’s Tcr Bispecific Program Ima401.
Immatics - ‍​to Get Upfront Payment of $150 Million, Additional Milestone Payments of Upto $770 Million Plus Tiered Double-digit Royalties on Net Product Sales.
Immatics - ‍​terms of Current Agreement Regarding Immatics’ Tcer Ima401 Program Exclude Any Magea4/8 Targets for Cell Therapy.
((reuters.
Briefs@thomsonreuters.
Com;)).